Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02703818
Other study ID # CA2015-4 US
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 2016
Est. completion date May 2018

Study information

Verified date November 2018
Source Nevro Corp
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, multi-center post-market study of the Senza System in subjects with chronic, intractable pain of the upper extremities. Data at follow-up visits will be compared to Baseline data collected at the beginning of the study.


Recruitment information / eligibility

Status Completed
Enrollment 64
Est. completion date May 2018
Est. primary completion date August 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Key Inclusion Criteria:

1. Have been diagnosed with chronic, intractable pain of an upper extremity of neuropathic origin, which has been refractory to conservative therapy for a minimum of 3 months.

2. Have an average pain intensity (over a period of 7 days) of an upper extremity of = 5 out of 10 cm on the Visual Analog Scale (VAS) at enrollment.

3. Be on stable pain medications for at least 28 days and be willing to stay on those medications with no dose adjustments until activation of the permanently implanted SCS device.

4. Be 18 years of age or older at the time of enrollment.

5. Be an appropriate candidate for the surgical procedures required in this study.

6. Be capable of subjective evaluation, able to read and understand English-written questionnaires, and are able to read, understand and sign the written inform consent in English.

7. Have stable neurological status measured by motor, sensory and reflex function.

Key Exclusion Criteria:

1. Have a medical condition or pain in other area(s), not intended to be treated with SCS, that could interfere with study procedures.

2. Have a current diagnosis of a progressive neurological disease.

3. Have a current diagnosis or condition such as a coagulation disorder, bleeding diathesis, platelet dysfunction, progressive peripheral vascular disease or uncontrolled diabetes mellitus that presents excess risk for performing the procedure.

4. Have mechanical spine instability as determined.

5. Have significant stenosis, based on MRI.

6. Have an existing drug pump and/or another active implantable device (switched on or off) such as a pacemaker or other SCS devices.

7. Have a condition currently requiring or likely to require the use of whole body MRI or diathermy.

8. Be pregnant (if female and sexually active, subject must be using a reliable form of birth control, be surgically sterile or be at least 2 years post-menopausal).

9. Have within 6 months of enrollment a significant untreated addiction to dependency producing medications, alcohol or illicit drugs.

10. Be involved in an injury claim under current litigation.

11. Have a pending or approved worker's compensation claim.

12. Have evidence of an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance of intervention and/or ability to evaluate treatment outcome, as determined by a psychologist.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Senza
Spinal Cord Stimulation

Locations

Country Name City State
United States NEVRO Corp Redwood City California

Sponsors (1)

Lead Sponsor Collaborator
Nevro Corp

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Responder Rate 3 months
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01009385 - Cervical Epidural Pressure Measurement N/A